Validation of LC-MS/MS bioanalytical methods for protein therapeutics

Bioanalysis

Volumn 6, Issue 13, 2014, Pages 1739-1742

  Vazvaei, Faye ^a   Duggan, Jeffrey X ^b  

^a Roche Pharma Research and Early Development Roche Innovation Center New York Roche TCRC Inc   (United States)

^b BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

Author keywords

enzymatic digestion; hybrid methods; PrD LC MS; protein digestion LC MS MS; quantitative protein LC MS MS; regulated biotherapeutic bioanalysis; validation

Indexed keywords

PEPTIDE; PROTEIN; REAGENT; ENZYME; LIGAND;

ACCURACY; CONCENTRATION (PARAMETERS); DRUG SENSITIVITY; GOOD LABORATORY PRACTICE; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; NOMENCLATURE; PROTEIN DEGRADATION; PROTEIN STABILITY; RECEPTOR BINDING ASSAY; REVIEW; STANDARD; VALIDATION PROCESS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; METABOLISM; STANDARDS; TANDEM MASS SPECTROMETRY;

CHROMATOGRAPHY, HIGH PRESSURE LIQUID; ENZYMES; HUMANS; LIGANDS; PROTEINS; REFERENCE STANDARDS; TANDEM MASS SPECTROMETRY;

EID: 84906699468     PISSN: 17576180     EISSN: 17576199     Source Type: Journal    
DOI: 10.4155/bio.14.125     Document Type: Review

References (12)

1. Li F, Fast D, Michael S. Absolute quantitation of protein therapeutics in biological matrices by enzymatic digestion and LC-MS. Bioanalysis 3(21), 2459-2480 (2011).
2. Ewles M, Goodwin L. Bioanalytical approaches to analyzing peptides and proteins by LC-MS/MS. Bioanalysis 3(12), 1379-1397 (2011).
3. Ezan E, Bitsch F. Critical comparison of MS and immunoassays for the bioanalysis of therapeutic antibodies. Bioanalysis 1(8), 1375-1388 (2009).
4. van den Broek I, Niessen WM, van Dongen WD. Bioanalytical LC-MS/MS of protein-based biopharmaceuticals. J. Chromatogr. B 929, 161-179 (2013).
5. Wang SJ, Wu ST, Gokemeijer J et al. Attribution of the discrepancy between ELISA and LC-MS/MS assay results of a PEGylated scaffold protein in post-dose monkey plasma samples due to the presence of anti-drug antibodies. Anal. Bioanal. Chem. 402(3), 1229-1239 (2012).
6. Szapacs ME, Urbanski JJ, Kehler JR et al. Absolute quantification of a therapeutic domain antibody using ultraperformance liquid chromatography-mass spectrometry and immunoassay. Bioanalysis 2(1), 1597-1608 (2010).
7. Whiteaker JR, Zhao L, Abbatiello SE et al. Evaluation of large scale quantitative proteomic assay development using peptide affinity-based mass spectrometry. Mol. Cell. Proteomics 10, M110.005645 (2011).
8. European Medicines Agency, Committee for Medicinal Products for Human Use (CHMP). Guideline on Bioanalytical Method Validation. European Medicines Agency, London, UK (2011).
9. Bioanalytical Method Validation. Draft Guidance. US FDA, Rockville, MD, USA (2013).
10. Knutsson M, Schmidt R, Timmerman P. LC-MS/MS of large molecules in a regulated bioanalytical environment - which acceptance criteria to apply? Bioanalysis 5(18), 2211-2214 (2013).
11. Guidance for Industry: Bioanalytical Method Validation. US FDA, Rockville, MD, USA (2001).
12. Viswanathan CT, Bansal S, Booth B et al. Quantitative bioanalytical methods validation and implementation: best practices for chromatographic and ligand binding assays. Pharm. Res. 24(10), 1962-1973 (2007).